Gilead said it entered into settlement agreements (the "Agreements") on October 6, 2025 to resolve patent litigation with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd. over Biktarvy.

8-KRegulation FD DisclosureFiled Oct 6, 2025Period of report Oct 6, 2025Summary published (UTC) Oct 12, 2026

Key points

AI summary

Gilead said it entered into settlement agreements (the "Agreements") on October 6, 2025 to resolve patent litigation with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd. over Biktarvy.
The company explained that Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., the counterparties to the settlements, are generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration to market generic versions of Biktarvy.
Gilead said that under the Agreements, no generic entry of Biktarvy tablets containing bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg is expected in the United States before April 1, 2036.
The company said the Agreements are subject to standard acceleration provisions. It also said it does not consider the Item 7.01 information in this filing to be filed under Section 18 of the Exchange Act.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Gilead Biktarvy Patent Litigation Settlements

Gilead said it entered into settlement agreements (the "Agreements") on October 6, 2025 to resolve patent litigation with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd. over Biktarvy.

Source · Based on the filing body and exhibits

Three Generic Manufacturers File ANDAs

The company explained that Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., the counterparties to the settlements, are generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration to market generic versions of Biktarvy.

Source · Based on the filing body and exhibits

U.S. Generic Entry Timing

Gilead said that under the Agreements, no generic entry of Biktarvy tablets containing bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg is expected in the United States before April 1, 2036.

Source · Based on the filing body and exhibits

Acceleration Provisions in Settlements

The company said the Agreements are subject to standard acceleration provisions. It also said it does not consider the Item 7.01 information in this filing to be filed under Section 18 of the Exchange Act.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.